Signs of diabetes and/or autoimmunity may include persistent excessive thirst or not feeling thirsty, frequent urination, increased urination, dark urine, blurred vision, dry mouth, loss of weight, abdominal or back pain, and loss of appetite. Often the symptoms are similar to symptoms of other illnesses, leading to long-term illness.\n
Although, the precise mechanism of islets destruction at a cellular level, autoimmunity has been demonstrated as very important role in the pathogenesis of diabetes. There is a lot of evidence to support that autoimmune process can be cured in human. Diabetes, auto-immune could be cured just by proper therapy in the right period of time. For the patients have diabetes over the age of 60 years, autoimmune process can be cured too. Patients with diabetes, who are in pain, but do not have any symptom, could be cured immediately through proper therapy.
As of 2012, 9.7 million people, or 10.6 % of the U.S. population, had type 1 diabetes. Among the 2.2 million people with type 2 diabetes, 1.2 million (64% of these patients) had an autoimmune diagnosis. As a whole, there were nearly 9.9 million people with an autoimmune diagnosis in the U.S, including 3.6 million with type 1 diabetes.
In an adult, non-obese man with diabetes, the presence of autoimmune dysfunction as determined by increased body mass index, diabetes duration, abnormal\nglycemic control, or use of immunosuppressive medications is uncommon.
Diabetics are frequently treated with insulin for type 1 diabetes, and many also have other autoimmunity. Treatment may include lifestyle adjustments, diet, regular physical activity, and medications for high blood pressure, diabetic foot, hypercholesterolemia, and blood pressure. Treatment for autoimmune diseases can include antispasmodic and/or anticholinergic medications. Immunosuppressants can be prescribed for autoimmune diseases, particularly for steroid-refractory disease.
Treatment with VX-880 substantially improved quality of life, including symptoms of depression, anxiety, and fatigue, as measured by the WHOQOL in patients with early-stage NIPA at the time of initiating VX-880. Results from a recent clinical trial confirm the efficacy of VX-880 in patients with NIPA and identify new improvements in quality of life with treatment.
At present, clinical trials are being limited mainly to diabetes. As a result, only a small proportion of trials and patients is involved in assessing the effect of a new diabetes treatments. Clinical trials of alternative treatments for autoimmune disease must be developed to offer new treatments to patients for whom existing therapies do not offer long term control of disease symptoms.
Vx-880 is a potentially useful agent for treating rheumatoid arthritis and psoriasis but does appear to have a potential adverse effect profile which may require special consideration before starting it. It is also unclear whether it is safe at the lower doses used in psoriasis.
So far, vx-880 hasn't been shown to be an effective agent for treatment of any autoimmune disorder like insulin-dependent diabetes. Moreover, there isn't much research on vx-880 so we don't have much definitive answer as to whether or not it is effective to treat autoimmune disorders like diabetes.
Results from a recent paper showed that the anti-cancer effects of VX-880 in MCF-7 cell lines can be attributed to a number of possible mechanisms like caspase-dependent apoptosis, cell cycle regulation and induction of antioxidant pathways.
The discovery of new drugs to treat [severe non-obese type 2 diabetes mellitus] and/or autoimmune disorders will [be very difficult] to achieve in the near future as it takes several years (up to 10 years) before a drug is available that meets the standards of a "gold-standard" treatment.